Pune, India | November 17, 2025
Regeneron Pharmaceuticals will present new data across 14 abstracts at the American Society of Hematology (ASH) 2025 Annual Meeting. Specifically, the event runs from December 6 to 9 in Orlando, Florida. Together, these findings mark a significant leap in treating blood cancers and rare blood disorders. Moreover, they highlight Regeneron’s leadership in hematology drug development and innovative therapies. In addition, the data showcase major advances and reinforce the company’s commitment to addressing unmet needs in hematologic diseases.
For instance, a key highlight is Regeneron’s bispecific antibody, Lynozyfic (linvoseltamab-gcpt). The Phase 1/2 LINKER-MM4 trial demonstrated promising results. Importantly, this trial represents the first evaluation of a BCMA×CD3 bispecific antibody as a monotherapy in newly diagnosed multiple myeloma patients. Regeneron will furthermore present updated findings from the ongoing LINKER-MM2 study. In that study, Lynozyfic was combined with two different anti-CD38 monoclonal antibodies for patients with relapsed or refractory multiple myeloma. Consequently, these studies may reshape early treatment strategies for multiple myeloma.
Regeneron is additionally advancing lymphoma treatment through its odronextamab program. The OLYMPIA-3 trial shows that odronextamab combined with chemotherapy—without rituximab—can work as frontline therapy for diffuse large B-cell lymphoma (DLBCL). The company will also share results from odronextamab studies in follicular lymphoma. These include frontline treatment from OLYMPIA-2 and relapsed or refractory disease treatment from OLYMPIA-5, where odronextamab was combined with lenalidomide. Therefore, these findings expand the potential use of bispecific antibodies in lymphoma care.
Beyond cancer, Regeneron is progressing in rare blood disorders. Updated data will focus on the novel combination of cemdisiran with pozelimab in paroxysmal nocturnal hemoglobinuria (PNH) patients. Moreover, this approach will be compared directly with ravulizumab. As a result, the research may influence future standards of care for complement-mediated diseases. Regeneron will also present first-in-human data for REGN7257, which targets patients with severe aplastic anemia who did not respond or relapsed after immunosuppressive therapy. Thus, this addresses a critical unmet need.
L. Andres Sirulnik, M.D., Ph.D., Senior Vice President and Head of Hematology Clinical Development, described 2025 as a landmark year for Regeneron’s hematology program. He explained that oral presentations of Lynozyfic and frontline odronextamab demonstrate how early intervention with innovative therapies can benefit more patients. Additionally, Sirulnik emphasized that the updated data reflect Regeneron’s strategy of leveraging deep hematology expertise to make meaningful progress where unmet needs remain high.
To engage investors and stakeholders, Regeneron will host a virtual “Regeneron Roundtable” on December 10 at 8:30 a.m. ET. During the event, the company will provide detailed insights into its multiple myeloma development program. Regeneron’s presence at ASH 2025 demonstrates its ambition to tackle blood cancers and disorders with advanced therapies, including bispecific antibodies and RNA-based approaches. If early results hold, these data could transform hematology treatment, offering hope to patients with multiple myeloma, lymphoma, PNH, and aplastic anemia.
Overall, this comprehensive presentation highlights Regeneron’s commitment to innovation and improving patient outcomes. Furthermore, the company continues translating scientific discovery into practical therapies that address critical gaps in hematology care. Therefore, such progress positions Regeneron as a pioneer in developing customized, potentially synergistic treatments that may redefine standards of care in hematologic diseases.
